Legend Biotech (LEGN) Total Debt (2021 - 2026)

Legend Biotech (LEGN) has reported Total Debt for 6 consecutive years, with $266.0 million the latest figure, recorded in Q1 2026.

• Quarterly Total Debt fell 13.0% year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.0 million (down 13.0% YoY) and the FY2025 annual result came in at $638.2 million, up 111.89% from the prior year.
• Total Debt retreated to $266.0 million in Q1 2026 per LEGN's latest filing, from $638.2 million in the prior quarter.
• Over the last five years, Total Debt for LEGN reached as high as $638.2 million in Q4 2025 and fell as low as $126.7 million in Q1 2022.
• A 5-year average of $299.5 million and a median of $286.4 million in 2024 frame the typical range for Total Debt.
• Annual changes were most pronounced in 2022 — Total Debt soared 116.61% — and 2026, when it decreased 13.0%.
• Year by year, Total Debt stood at $260.9 million in 2022, then climbed by 7.82% to $281.3 million in 2023, then rose by 7.06% to $301.2 million in 2024, then surged by 111.89% to $638.2 million in 2025, then sank by 58.32% to $266.0 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $266.0 million, $638.2 million, and $314.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.